0ME.SG - Twist Bioscience Corp
| Previous close | 13.33 |
| Open | 13.37 |
| Bid | 14.15 x 280000 |
| Ask | 14.34 x 190000 |
| Day's range | 13.37 - 14.39 |
| 52-week range | 10.37 - 57.82 |
| Volume | |
| Avg. volume | 6 |
| Market cap | N/A |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Business Wire
Twist Bioscience to Present at Upcoming Investor Conferences
SOUTH SAN FRANCISCO, Calif., May 24, 2023--Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced that Emily M. Leproust, Ph.D., CEO and co-founder of Twist Bioscience, and Jim Thorburn, CFO of Twist Bioscience, will present at the following upcoming investor conferences:
- Business Wire
Twist Bioscience Appoints Robert Werner as Chief Accounting Officer
SOUTH SAN FRANCISCO, Calif., May 23, 2023--Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced the appointment of Robert Werner as chief accounting officer.
- Business Wire
Twist Bioscience Launches Portfolio of RNA Sequencing Tools
SOUTH SAN FRANCISCO, Calif., May 22, 2023--Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced the launch of a portfolio of RNA sequencing tools, which includes the Twist RNA Exome, Twist RNA Library Prep Kit and the Twist Ribosomal RNA (rRNA) & Hemoglobin (Globin) Depletion Kit, as well as custom target enrichment capabilities for RNA and whole transcriptome sequencing
- Business Wire
Twist Bioscience to Present at ITF World 2023
SOUTH SAN FRANCISCO, Calif., May 10, 2023--Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced that Emily M. Leproust, Ph.D., CEO and co-founder of Twist Bioscience, will present at Imec Technology Forum (ITF) World 2023 in Antwerp, Belgium on Wednesday, May 17th at 11:10 AM CEST.
- Business Wire
Twist Bioscience Reports Fiscal Second Quarter 2023 Financial Results
SOUTH SAN FRANCISCO, Calif., May 05, 2023--Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today reported financial results and business highlights for the second quarter of fiscal 2023 ended March 31, 2023.
- Business Wire
Twist Bioscience and Aster Insights Partner on Launch of Next Generation Oncology Panel for Cancer Research
SOUTH SAN FRANCISCO, Calif. & TAMPA, Fla., April 27, 2023--Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, and Aster Insights, a bioinformatics company with the most advanced, direct-patient, lifetime-consented clinicogenomics data to accelerate oncology discovery research, today announced the availability of the AsterExome panel, which can simultaneously enable whole exome sequenc
- Business Wire
Twist Bioscience Enters into Third Collaboration with Astellas to Support Antibody Discovery for Immunotherapies
SOUTH SAN FRANCISCO, Calif., April 20, 2023--Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced a collaboration with Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura., "Astellas"), by which Astellas will license a suite of Twist’s VHH antibody libraries to be used by Astellas for drug discovery and development.
- Business Wire
Twist Bioscience Launches TCR and CAR Libraries to Enable the Development of Cell Therapies
SOUTH SAN FRANCISCO, Calif., April 13, 2023--Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced the launch of Twist T-cell Receptor (TCR), and Twist chimeric antigen receptor (CAR) Libraries. These new libraries provide researchers with the ability to rapidly create custom libraries that can enable the identification and development of next generation cell therapies.
- Business Wire
Twist Bioscience to Report Fiscal 2023 Second Quarter Financial Results on Friday, May 5, 2023
SOUTH SAN FRANCISCO, April 13, 2023--Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced that it will issue its financial results for the fiscal 2023 second quarter ended March 31, 2023, before the opening of the market on Friday, May 5, 2023. The company plans to hold a conference call and live audio webcast for analysts and investors at 8:00 a.m. Eastern Time to discu
- Business Wire
DNA Data Storage Alliance Announces Board Appointments
SAN DIEGO, March 29, 2023--The DNA Data Storage Alliance, a SNIA Technology Affiliate, formed in 2020 by Illumina, Inc. (NASDAQ: ILMN), Microsoft (Nasdaq: MSFT), Twist Bioscience Corporation (NASDAQ: TWST) and Western Digital (NASDAQ: WDC) to create and promote an interoperable storage ecosystem based on DNA as a data storage medium, today announced the appointments of CATALOG Technologies and Quantum Corporation to the governing board of the Alliance. David Turek will represent CATALOG and Don
- Business Wire
Twist Bioscience Announces Robust Antibody Discovery Services Integrating In Vivo, In Vitro and In Silico Approaches
SOUTH SAN FRANCISCO, Calif., March 09, 2023--Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced an integrated offering of antibody discovery services available to customers. The offering combines Twist Biopharma’s synthetic libraries and AI machine learning with an in vivo immunization approach gained through the acquisition of Abveris, also known as Twist Boston. This
- Business Wire
Twist Bioscience Publishes Data on VHH Single Domain Antibody Discovery Using New Methodology on Optofluidic Platform
SOUTH SAN FRANCISCO, Calif., February 14, 2023--Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today published on the successful discovery of alpaca-derived VHH antibodies using a disruptive, function-forward in vivo discovery workflow developed by Abveris, also known as Twist Boston, on the Beacon optofluidic platform. The paper, titled "Alpaca Single B Cell Interrogation and Hea
- Business Wire
Twist Bioscience Announces Technology Early Access of Enhanced Whole Genome Sequencing Solution at AGBT
SOUTH SAN FRANCISCO, Calif., February 07, 2023--Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced technology early access of the Twist enhanced Whole Genome Sequencing (eWGS) solution focused on non-human genomics applications, at the Advances in Genome Biology and Technology (AGBT) 2023 General Meeting in Hollywood, Florida. eWGS is a novel solution that enables rese
- Business Wire
Twist Bioscience Reports Fiscal First Quarter 2023 Financial Results
SOUTH SAN FRANCISCO, Calif., February 03, 2023--Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today reported financial results and business highlights for the first quarter of fiscal 2023 ended December 31, 2022.
- Business Wire
Twist Bioscience Begins Shipping Commercial Product from Synthetic DNA Manufacturing Factory of the Future
SOUTH SAN FRANCISCO, Calif., January 26, 2023--Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced the shipments of the first products from its second manufacturing site, the Factory of the Future, in Wilsonville, Oregon.
- Business Wire
Twist Bioscience to Report Fiscal 2023 First Quarter Financial Results on Friday, February 3, 2023
SOUTH SAN FRANCISCO, Calif., January 19, 2023--Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced that it will issue its financial results for the fiscal 2023 first quarter ended December 31, 2022, before the opening of the market on Friday, February 3, 2023. The company plans to hold a conference call and live audio webcast for analysts and investors at 8:00 a.m. East
- Business Wire
Twist Bioscience and CENTOGENE Launch Three Panels to Advance Rare Disease and Hereditary Cancer Research and Support Diagnostics
SOUTH SAN FRANCISCO, Calif. & CAMBRIDGE, Mass. & ROSTOCK, Germany & BERLIN, January 10, 2023--Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, and Centogene N.V. (Nasdaq: CNTG), the essential life science partner for data-driven answers in rare and neurodegenerative diseases, today announced the launch of three next-generation sequencing (NGS) target enrichment panels to support rar
- Business Wire
Twist Bioscience and Astellas Enter into Multitarget Antibody Discovery Research Collaboration
SOUTH SAN FRANCISCO, Calif., January 09, 2023--Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced a research collaboration with Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") to discover antibodies against multiple targets of interest to develop curative therapies for patients suffering from diseases that lack treatment options.
- Business Wire
Twist Bioscience to Present at the 41st Annual J.P. Morgan Health Care Conference
SOUTH SAN FRANCISCO, Calif., January 03, 2023--Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced that Emily M. Leproust, Ph.D., CEO and co-founder of Twist Bioscience, will present at the 41st Annual J.P. Morgan Health Care Conference on Monday, January 9th at 5:15 p.m. PST / 8:15 p.m. EST.
- Business Wire
Twist Bioscience to Present at 5th Annual Evercore ISI HealthCONx Conference
SOUTH SAN FRANCISCO, Calif., November 23, 2022--Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced that Emily M. Leproust, Ph.D., CEO and co-founder of Twist Bioscience, and Jim Thorburn, CFO of Twist Bioscience, will host a fireside chat and one-on-one meetings at the 5th Annual Evercore ISI HealthCONx Conference on Wednesday, November 30th at 4:20 p.m. Eastern Time.
- Business Wire
Twist Bioscience Reports Fiscal Fourth Quarter and Full Year Fiscal 2022 Financial Results
SOUTH SAN FRANCISCO, Calif., November 18, 2022--Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today reported financial results and business highlights for the fourth quarter and full year fiscal 2022 ended September 30, 2022.
- Business Wire
Twist Bioscience Addresses Misleading Short-Seller Report
SOUTH SAN FRANCISCO, Calif., November 15, 2022--Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today addressed a misleading short-seller report issued by Scorpion Capital.
- Business Wire
Twist Bioscience to Report Fiscal 2022 Fourth Quarter and Full Year Financial Results on Friday, November 18, 2022
SOUTH SAN FRANCISCO, Calif., November 03, 2022--Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced that it will issue its financial results for the fiscal 2022 fourth quarter and full year ended September 30, 2022, before the opening of the market on Friday, November 18, 2022. The company plans to hold a conference call and live audio webcast for analysts and investors
- Business Wire
Twist Bioscience and Illumina Partner to Produce Robust Exome Panel to Advance Research
SOUTH SAN FRANCISCO, Calif., November 02, 2022--Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, and Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced a partnership to provide expanded customer access to the co-branded Twist Bioscience® for Illumina® Exome 2.0 Plus panel designed to advance disease research. The panel can
- Business Wire
Twist Bioscience Promotes Patrick Finn, Ph.D., to President and Chief Operating Officer
SOUTH SAN FRANCISCO, Calif., October 26, 2022--Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced the promotion of Patrick Finn, Ph.D. to the newly created position of president and chief operating officer. Dr. Finn previously served as chief commercial officer of Twist Bioscience.
